The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index; 127 of the 264 sources its claims cite were checked for support.
Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights
Open accessAbstract
Review of clinical and preclinical evidence for itraconazole as a repurposed anticancer drug.
Overview
CoChat Summary
TL;DR
This paper is a 2021–2025 literature review on itraconazole (ITZ) as a repurposed anticancer agent, summarizing its chemistry, mechanisms, delivery systems, and evidence across multiple cancers. The review argues that ITZ has the strongest support as a combination or adjuvant therapy rather than a stand-alone anticancer drug.
Key findings
- The review identifies four main anticancer mechanisms for ITZ: autophagy induction, anti-angiogenesis, reversal of multidrug resistance, and Hedgehog (Hh) pathway inhibition.
- ITZ has reported activity across many cancer models, including NSCLC, prostate cancer, basal cell carcinoma, gastric cancer, colon cancer, pancreatic cancer, breast cancer, cervical/ovarian cancer, esophageal cancer, melanoma, and hemangioma endothelial cells.
- In advanced metastatic biliary tract cancer, combination oral ITZ solution produced a 57% response rate, with 2 complete responses and 14 partial responses after first-line chemotherapy.
- In advanced NSCLC, adding ITZ to platinum-based chemotherapy improved overall response rate and progression-free survival, but did not improve overall survival.
- In metastatic pancreatic cancer, a regimen including ITZ was given to 81 patients; 64% responded overall, median overall survival was 14.4 months, and median progression-free survival was 8.3 months.
Methods
- Narrative review of recent literature, focusing on studies from 2021–2025 about ITZ as a cancer therapy strategy.
- Literature search across Web of Science, Scopus, Google, PubMed, and Google Scholar using itraconazole-related anticancer keywords.
- The paper synthesizes preclinical studies, clinical trials, and drug-delivery studies rather than reporting a single original experiment.
Limitations
- The paper states that direct comparisons among drug-delivery systems are still scarce, and that a systematic assessment of encapsulation efficiency, release profile, bioavailability, toxicity, and anticancer activity is still needed.
- The review states that ITZ’s specific molecular targets across cancer types remain unclear, despite evidence for pathway-level effects.
- Evident from the text: many conclusions are based on preclinical models, small early-phase trials, or combination regimens, so the clinical evidence is uneven and often not definitive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Scheme 1 [Itraconazole synthesis], reproduced from ref. 14 with permission from Elsevier, Tetrahedron, and ref. 13 with permission from Elsevier, Journal of Medicinal Chemistry, copyright 2026.](https://figures.cochat.ai/paper-figures/94b80d9acdf04c16ab0d352d0a09da14/itraconazole-as-a-repurposed-anti-cancer-agent-focusing-on-synthesis-mechanisms-figure-2.jpg)
![Fig. 2 [Anticancer mechanisms of ITZ. (1) Autophagy induction: ITZ suppresses the AKT/mTOR pathway, promoting autophagic cell death and inhibiting glioblastoma cell growth, partly through altered cholesterol trafficking. (2) Anti-angiogenic activity: ITZ inhibits angiogenesis via AMPK activation and mTOR suppression, mediated by VDAC1 targeting and disruption of cholesterol transport through NPC1. (3) Reversal of multidrug resistance: ITZ inhibits CYP3A4 activity, contributing to reduced drug metabolism and enhanced chemosensitivity. (4) Hh pathway inhibition: ITZ blocks SMO and GLI signaling, leading to downregulation of oncogenic targets involved in proliferation, survival, angiogenesis, and drug resistance], reproduced from ref. 27 with permission from Elsevier, ACS Chemical Biology, and ref. 23 with permission from Elsevier, Journal of Advanced Research, copyright 2026.](https://figures.cochat.ai/paper-figures/1583fa86e1cb4ad3917c0f44fea9de33/itraconazole-as-a-repurposed-anti-cancer-agent-focusing-on-synthesis-mechanisms-figure-2.jpg)



Verification
Claims the paper makes
115 Valid · 5 Not valid · 122 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“EAC was substantially lower in control 10 of 31 (32%), compared to ITZ 2 of 24 (8%) (P = 0.033).”
§ Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights > Esophageal cancer
What the sources say
- Disputedcites [84] sourceExperimental — accuracy not yet measured
The Results (Preclinical Levrat Model) report the same counts and P value, but state the opposite comparison: EAC was lower in itraconazole-treated rats (2/24, 8.3%) than in controls (10/31, 32.3%). The claim reverses which group had the lower incidence. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plainstates a causen = 31 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Regarding hedgehog signaling pathway, its synergy with docetaxel has been inferred against prostate and MCF-7 drug-resistant-breast cancer cells, though prior mechanisms has been also stated.85,94,95”
§ Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights > Synergistic, additive and antagonistic effects of itraconazole with anticancer drugs
What the sources say
- Disputedcites [85] sourceExperimental — accuracy not yet measured
The Results report that itraconazole reversed docetaxel resistance in prostate cancer cell lines, but explicitly say it failed to reverse resistance in MCF-7R breast cancer cells. The Discussion attributes the observed prostate-cell effect to ABCB1 inhibition, not an established hedgehog-signaling mechanism. Page numbers are not available in the supplied copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [94] sourceExperimental — accuracy not yet measured
The Results report that itraconazole combined with docetaxel reversed resistance in prostate cancer cell lines (Figure 2). But the breast cancer Results state that itraconazole failed to reverse docetaxel resistance in MCF-7R cells (Figure 3A), contrary to that part of the claim. The Discussion attributes the observed effect to ABCB1 inhibition, not to hedgehog-pathway inhibition. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [95] source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“By blocking SMO and/or GLI, particularly GLI1, and their downstream targets through a variety of mechanisms, ITZ has been shown to suppress the Hh pathway.”
§ Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights > Mechanisms of action
What the sources say
- Partly supportedcites [41] sourceExperimental — accuracy not yet measured
The Discussion and Conclusions section says preliminary evidence indicates that itraconazole inhibits Hedgehog signaling through SMO, and the Results report reduced GLI1 mRNA expression. It does not establish that itraconazole directly blocks GLI1 or its downstream targets, or that it suppresses the pathway through a variety of mechanisms. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [42] sourceExperimental — accuracy not yet measured
The Results (section on GDC-0449-resistant SMO) show that itraconazole inhibits SMO-mediated Hedgehog activity, and the tumor Results report reduced Gli1 mRNA. But the GLI2-overexpression Results say itraconazole acts upstream of GLI2 and does not inhibit activity induced by GLI2 overexpression. The paper therefore does not establish that itraconazole directly blocks GLI, particularly GLI1, or that it does so through a variety of mechanisms. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since mTOR signaling and proliferation in HUVEC were also inhibited by either genetically knocking down NPC1 or NPC2 or by pharmacologically inhibiting cholesterol trafficking with two other known NPC-inducing small molecules, imipramine and U18666A albeit at far higher concentrations than ITZ, it was also deciphered to cease cholesterol trafficking resulting in mTOR inhibition.26,27”
§ Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights > Mechanisms of action
What the sources say
- Could not verifycites [26] sourceExperimental — accuracy not yet measured
The Etiology sections describe impaired cholesterol export in NPC1- or NPC2-deficient cells, but do not address itraconazole or mTOR inhibition. Searches for itraconazole, mTOR, and the proposed trafficking-to-mTOR link found no passage supporting that claim. (LLM, conf=0.76)
- Supportedcites [27] source
The Abstract states that itraconazole inhibits cholesterol trafficking through NPC1 and that this contributes to mTOR inhibition. The Results and Discussion summary also identifies cholesterol-trafficking inhibition as one of itraconazole’s two upstream mechanisms of mTOR inhibition; the other is AMPK activation. No page numbers are supplied in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“ITZ was discovered to cause autophagic cell growth arrest in C6 and U87 glioblastoma cells in a mouse xenograft (U87) model as well as in vitro.21”
§ Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights > Mechanisms of action
What the sources say
- Supportedcites [21] source
The proliferation results report that itraconazole reduced growth of both U87 and C6 cells in vitro. The tumor xenograft and autophagy sections report reduced growth and increased autophagy markers in itraconazole-treated mouse U87 xenografts. The supplied passages do not specify page numbers. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
135 more claims · 61 with their cited sources checked
Create a free account to see all 261 claims and to verify the 18 references still open.
- It may state two separate claims as one. 113
- Probably not a substantial claim. 12
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Li, 2022, Biomed. Pharmacother., 154, 113616, 10.1016/j.biopha.2022.113616”
Cited work 10.1016/j.biopha.2022.113616 · retracted 2022-10-01 · notice 10.1016/j.biopha.2022.113616 · this paper published 2026
Citations
Cites
1 retracted
Li, C.-L., Fang, Z.-X., Wu, Z., Hou, Y.-Y., Wu, H.-T., & Liu, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113616 · Cited by 46
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Vanier, M. T. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-16 · Cited by 1,222
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., Chong, C. R., Chang, K. S., Fereshteh, M., Gardner, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.027 · Cited by 527
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
Tissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426
Kim, J., Aftab, B. T., Tang, J. Y., Kim, D., Lee, A. H., Rezaee, M., Kim, J., Chen, B., King, E. M., Borodovsky, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.017 · Cited by 346
Kim, D. J., Kim, J., Spaunhurst, K., Montoya, J., Khodosh, R., Chandra, K., Fu, T., Gilliam, A., Molgo, M., Beachy, P. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9525 · Cited by 289
De Beule, K., & Van Gestel, J. (2001) · Drugs · doi:10.2165/00003495-200161001-00003 · Cited by 283
Research works printed but not linked: 13
- Pantziarka, 2016, Ecancermedicalscience, 10, 610
- Pantziarka, 2015, Ecancermedicalscience, 9, 521
- Alzahrani, 2020, Oxid. Med. Cell. Longev., 2020, 3028387
- Cucchi, 2012, J. Exp. Pharmacol., 173
- Tsubamoto, 2015, Anticancer Res., 35, 4923
- N. S.Reddy , R.Vijitha and K.Rao , Polymer electrolyte membranes for fuel cell and drug delivery applications , KROS Publications , Cuddapah, India , 2021 , pp. 95–134
- Kudi, 2024, Drug Dev. Ind. Pharm., 1
- Bonthala, 2024, Journal of Integrative Natural Science, 17, 141
- El-kammar, 2024, Egyptian Journal of Histology, 47, 389
- Lima, 2022, Front. Pharmacol, 13, 869461, 10.3389/fphar.2022.869461 · DOI · Paper page
- Huang, 2025, Expert Opin. Drug Saf., 23, 87
- Somchit, 2009, J. Toxicol., 2009, 912320
- Wagh, 2012, Int. Scholarly Res. Not., 2012, 653465
Metadata
- Authors
- Marzi, M., Ghasemian, A., Ghanbariasad, A., Nournia, E., & Zarenezhad, E.
- Affiliations
- Fasa University of Medical Sciences (IR)
- Corresponding author
- Zarenezhad, Elham
- Venue
- RSC Advances
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2026
- Volume
- 16
- Issue
- 28
- Pages
- 25651-25674
- ISSN
- 2046-2069 (ISSN-L)
- PMC
- PMC13182516
- OpenAlex
- W7161145431
- Cited by
- 0
- References
- 97
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- RSC Advances (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Fasa University of Medical Sciences
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Keywords
- itraconazole, drug repurposing, anticancer agents, triazole antifungals, angiogenesis inhibition, signaling pathway modulation, drug synthesis, drug delivery systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights. https://app.cochat.ai/papers/10.1039/d5ra09799a
- The paper
- Marzi, M., Ghasemian, A., Ghanbariasad, A., Nournia, E., & Zarenezhad, E. (2026). Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights. RSC Advances. https://doi.org/10.1039/d5ra09799a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.